NCT07339878招募中不适用
Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma: Observational, Multicenter, Real-world Study
University Hospital, Strasbourg, France1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2025年4月20日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Description of the clinical characteristics of patients recently treated with first-line metastatic therapy for urothelial carcinoma
研究概览
简要总结
The standard first-line treatment for metastatic urothelial carcinoma has become the combination of Enfortumab Vedotin and Pembrolizumab following the publication of the EV-302 study results at the end of 2024. Another standard remains in 2025 for patients who are not eligible for the EV Pembrolizumab combination, namely platinum-based chemotherapy +/- avelumab in cases of non-progression. The objective of the FLORAL study is to determine the characteristics of these patients and the reasons that led clinicians to prefer a first-line treatment based on platinum salts.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients over 18 years of age
- •Metastatic urothelial carcinoma
- •Treated with first-line metastatic therapy since October 2024
排除标准
- •Patient who expressed opposition to participating in the study
结局指标
主要结局
Description of the clinical characteristics of patients recently treated with first-line metastatic therapy for urothelial carcinoma
时间窗: Up to 12 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal CancerNCT07333651Li Min90
尚未招募
2 期
Image-Guided 125I Seed Implantation Plus Standard Systemic Therapy for Patients With Multiple Metastatic LesionsNCT07333664Li Min120
招募中
1 期
Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell LymphomasNCT07278856City of Hope Medical Center20
进行中（未招募）
1 期
Sequential first-line therapy in metastatic colorectal cancer with Capecitabine/FUFA, Irinotecan and Bevacizumabmetastatic colorectal cancerMedDRA version: 20.0 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 100000004864EUCTR2009-013099-38-DEKlinikum der Universität München, Anstalt des öffentlichen Rechts vertreten durch den Vorstand450
尚未招募
不适用
Evaluating the Predictive Capability of Transcriptomic Profiling for Identifying the Primary Site of Metastatic TumorsNCT07319949Fudan University30